-
Member
Msb
Biotech Company who has done some successful trials on Ventilator patients with COVID-19. Shares doubled in US on Friday, expecting huge opening on ASX this morning, will be fun to watch.
Disc: HOLD
-
Member
Will MSB end up the most expensive stock on the Aust market. Looks like it could be DYOR.
-
-
Its maniacal on the H/C thread. Serial cap raises ,re$ 600 mill in last 6 or 7 years and still losing heaps$. Huge leap of faith . Avoid imo until they actually start making money, if they ever do. Promises ,promises.
-
Dropped 31% today on an iminent decision. Is MSB the real deal, alot of runs to the exit for this traders plaything?Reality bites?
Update on Scheduled FDA Advisory Committee Meeting
-
Member
Down more today. Inside info, or just nerves? From a brief glance, the data wasn't as good as I would of liked and if we compare it with ivermectin taken with two other already FDA approved treatments, then the cost of stemcells makes it look very unattractive.....but on the flipside, I invested ... Despite knowibg this,
-
Member
what a difference 2 days can make - FDA approval voted 9-1, share back to trading.
-
On a string back to where it was but no further!? Boing.
Download Document 117.69KB
-
Member
Originally Posted by Joshuatree
Yes, thats the disappointing aspect, thought it would be up around mid to late 5's if not 6. More to come.
-
Originally Posted by Joshuatree
Its maniacal on the H/C thread. Serial cap raises ,re$ 600 mill in last 6 or 7 years and still losing heaps$. Huge leap of faith . Avoid imo until they actually start making money, if they ever do. Promises ,promises.
Try not to let the truth stand in the way of a good slap down on share-trader. MSB have been making money, not in profit yet, but in my opinion Alogenic stem cells are the future of medicine, and I will stick my neck out and say that "I believe MSB is the 'Tesla' of medicine. My only caveat is that 'big-pharma' is so powerful that they alone could kill this, so they can keep on pedaling their pills.
MSB Financial Highlights for the First Quarter FY2020
46% growth in revenue due to:
43% increase in milestone revenues from strategic partnerships (US$15.0 million compared with US$10.5 million for the first quarter of FY2019).
85% growth in revenues from sales of TEMCELL®1 HS. Inj. by Mesoblast’s licensee for steroid refractory acute graft versus host disease (aGVHD) in Japan compared to the first quarter of FY2019.
MCS have been saving lives of children under 12yo in Japan, and the recent ODAC vote was to recommend to the FDA that they approve MSC,s for use for this same condition for children in the USA,
It just "turn's out" that the same 'over reaction' of the infants immune system is what is causing so many covid19 deaths.( ARDS ) and any day now there will be the first read out of the 300 patient, double blind trial of MCS on covid patients on ventillators in the US. That will be the day when this stops being a 'Traders plaything'
PENN (happy holder- not advice!)
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks